Loading
Life sciences · Journal article
Ukrainian Journal of Urology · September 10, 2026
A consensus or society position rather than new primary data.
This is a clinical guidance article synthesizing existing recommendations on bone health management in oncourology patients. It recommends baseline osteoporosis screening and therapy for prostate cancer patients on androgen deprivation therapy, particularly those aged ≥75 years, and proposes β-CrossLaps monitoring every 3–6 months, with vitamin D supplementation at 400–800 IU/day paired with adequate calcium.
Narrative review of guidelines and literature. Patients with urological malignancies (kidney, prostate, bladder cancer) being considered for bone fracture prevention strategies.. Intervention: Bone fracture prevention strategies in oncourology: baseline osteoporosis therapy, β-CrossLaps screening, vitamin D supplementation (400–800 IU/day), and calcium intake.. Not specified; Ukrainian and international guidelines reviewed..
Rapid bone mineral density loss occurs during first 6–12 months of androgen deprivation therapy in prostate cancer patients Patients aged 75 and older with non-metastatic prostate cancer and comorbidities should initiate baseline osteoporosis therapy regardless of cancer treatment β-CrossLaps screening recommended at initial diagnosis then every 3–6 months to monitor therapy adherence and detect osteoporosis risk early
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should implement baseline bone health assessment and therapy for prostate cancer patients initiating androgen deprivation, establish regular β-CrossLaps monitoring schedules, and individualize vitamin D dosing. The guidance emphasizes early detection and management of osteoporosis as a concurrent condition or treatment adverse effect in oncourology.
A narrative review synthesizing clinical guidelines and recommendations on bone fracture prevention in oncourology patients, offering expert consensus rather than original research evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should implement baseline bone health assessment and therapy for prostate cancer patients initiating androgen deprivation, establish regular β-CrossLaps monitoring schedules, and individualize vitamin D dosing. The guidance emphasizes early detection and management of osteoporosis as a concurrent condition or treatment adverse effect in oncourology.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Bone health is an important factor to consider in the treatment of patients in oncourology. Patients and their relatives often have a low level of awareness regarding the potential risks of osteoporosis. This article contains information that may be useful for physicians in the decision-making process aimed at preventing bone fractures in patients with urological malignancies.MATERIALS AND METHODS. In the process of preparing this article, Ukrainian and international recommendations and clinical guidelines on oncourological diseases, osteoporosis, and vitamin D were reviewed, as well as instructions for the medical use of medicinal products, the current texts of which were obtained from official electronic resources. In addition, printed and electronic publications available on the resources of the National Library of Medicine, Google, and PubMed were utilized. The information search was conducted using the following keywords: oncology, kidney cancer, prostate cancer, bladder cancer, guidelines/clinical guidelines, clinical trials, metabolism, vitamin D, osteoporosis, β-CrossLaps. The article also contains original observations, assumptions, and conclusions.CONCLUSIONS. Osteoporosis may present as a concurrent condition or an adverse effect of treatment in oncourological patients; therefore, it requires proper attention: patients should be advised to undergo diagnostic evaluation and be prescribed appropriate therapy. To prevent non-metastatic fractures, patients with prostate cancer (PCa) prescribed ADT should initiate baseline osteoporosis therapy immediately after the start of androgen deprivation (whether surgical or medical), given that rapid loss of bone mineral density occurs during the first 6–12 months of androgen deprivation therapy (ADT). Considering the risks of developing osteoporosis, it is advisable for patients aged 75 and older with non-metastatic prostate cancer and comorbidities to initiate baseline osteoporosis therapy for the prevention of non-metastatic fractures, regardless of their prostate cancer treatment. If androgen deprivation therapy continues for more than 6 months, consider antiresorptive therapy. The implementation of β-CrossLaps screening will make it possible not only to monitor the patient’s adherence to therapy and the effectiveness of the treatment but also to detect osteoporosis risk at an early stage, bone metastases and other diseases related to bone tissue metabolism disorders and recommend patients to undergo further laboratory and instrumental examinations and the prescription of appropriate therapy. In oncourology, it is advisable to perform β-CrossLaps screening according to a specific schedule: Initial diagnosis and then every 3–6 months. The dose of vitamin D should be adjusted individually, prescribing the lowest effective dose. Optimal daily vitamin D supplementation for osteoporosis in Ukraine is often reported as 400–800 IU/day (10–20 mcg/day). Vitamin D should be prescribed in combination with adequate calcium intake (dietary + supplements). For better absorption, the daily dose of vitamin D and calcium can be divided into 2–3 intakes, especially in patients with intestinal malabsorption. In individuals with chronic hepatic and/or renal disorders, the synthesis of 1,25(OH)2D may be reduced. It is advisable to prescribe hydroxylated forms of vitamin D to such patients. The 1,25(OH)2D blood test aids in the decision-making process regarding the prescription of the hydroxylated or non-hydroxylated form of vitamin D. Decline routine 25(OH)D screening and treatment of 25(OH)D levels.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.